Table 5.

The associations of homocysteine (quartiles) with amyloid-β load according to dementia status, presence of infarcts and time between baseline homocysteine assessment and death (OR, 95% CI)

	Q1	Q2	Q3	Q4
No dementia (n = 94)	Ref	1.06 (0.31–3.64)	0.72 (0.23–2.25)	0.75 (0.21–2.68)
With dementia (n = 168)	Ref	2.23 (0.86–5.76)	1.78 (0.68–4.62)	2.06 (0.78–5.42)
No cerebral infarcts (n = 103)	Ref	2.55 (0.75–8.68)	1.20 (0.39–3.73)	2.20 (0.64–6.83)
Cerebral infarcts (n = 159)	Ref	1.30 (0.51–3.28)	1.07 (0.41–2.79)	1.10 (0.41–2.92)
Follow-up ≤ 3.5 y (n = 132)	Ref	1.35 (0.34–4.24)	1.15 (0.38–3.47)	0.76 (0.24–2.37)
Follow-up > 3.5 y (n = 130)	Ref	2.26 (0.85–5.98)	1.48 (0.56–3.90)	2.52 (0.88–7.19)

Significant results (P < 0.05) are in bold, trends (P < 0.10) are in italics. Analyses are adjusted for age at death, duration of follow-up, gender, APOE4 allele, cardiovascular conditions, living in institutions, and use of vitamins. Cerebral infarcts refer to the presence of either macro- or microinfarcts. The 3.5 year cut-off for follow-up time in stratified analyses represents the median value for the duration of follow-up in the autopsy population. Homocysteine quartiles in the autopsy population were: Q1 ≤ 15.5 µmol/l, Q2 = 15.6–18.4 µmol/l, Q3 = 18.5–23.45 µmol/l, Q4 ≥ 23.5 µmol/l.